Disease specificity of autoantibodies to cytosolic 5 '-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10333045" target="_blank" >RIV/00216208:11110/16:10333045 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00023728:_____/16:N0000023
Výsledek na webu
<a href="http://dx.doi.org/10.1136/annrheumdis-2014-206691" target="_blank" >http://dx.doi.org/10.1136/annrheumdis-2014-206691</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/annrheumdis-2014-206691" target="_blank" >10.1136/annrheumdis-2014-206691</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Disease specificity of autoantibodies to cytosolic 5 '-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Popis výsledku v původním jazyce
Objectives The diagnosis of inclusion body myositis (IBM) can be challenging as it can be difficult to clinically distinguish from other forms of myositis, particularly polymyositis (PM). Recent studies have shown frequent presence of autoantibodies directed against cytosolic 5'-nucleotidase 1A (cN-1A) in patients with IBM. We therefore, examined the autoantigenicity and disease specificity of major epitopes of cN-1A in patients with sporadic IBM compared with healthy and disease controls. Methods Serum samples obtained from patients with IBM (n = 238), PM and dermatomyositis (DM) (n = 185), other autoimmune diseases (n = 246), other neuromuscular diseases (n = 93) and healthy controls (n = 35) were analysed for the presence of autoantibodies using immunodominant cN-1A peptide ELISAs. Results Autoantibodies directed against major epitopes of cN-1A were frequent in patients with IBM (37%) but not in PM, DM or non-autoimmune neuromuscular diseases (<5%). Anti-cN-1A reactivity was also observed in some other autoimmune diseases, particularly Sjgren's syndrome (SjS; 36%) and systemic lupus erythematosus (SLE; 20%). Conclusions In summary, we found frequent anti-cN1A autoantibodies in sera from patients with IBM. Heterogeneity in reactivity with the three immunodominant epitopes indicates that serological assays should not be limited to a distinct epitope region. The similar reactivities observed for SjS and SLE demonstrate the need to further investigate whether distinct IBM-specific epitopes exist.
Název v anglickém jazyce
Disease specificity of autoantibodies to cytosolic 5 '-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Popis výsledku anglicky
Objectives The diagnosis of inclusion body myositis (IBM) can be challenging as it can be difficult to clinically distinguish from other forms of myositis, particularly polymyositis (PM). Recent studies have shown frequent presence of autoantibodies directed against cytosolic 5'-nucleotidase 1A (cN-1A) in patients with IBM. We therefore, examined the autoantigenicity and disease specificity of major epitopes of cN-1A in patients with sporadic IBM compared with healthy and disease controls. Methods Serum samples obtained from patients with IBM (n = 238), PM and dermatomyositis (DM) (n = 185), other autoimmune diseases (n = 246), other neuromuscular diseases (n = 93) and healthy controls (n = 35) were analysed for the presence of autoantibodies using immunodominant cN-1A peptide ELISAs. Results Autoantibodies directed against major epitopes of cN-1A were frequent in patients with IBM (37%) but not in PM, DM or non-autoimmune neuromuscular diseases (<5%). Anti-cN-1A reactivity was also observed in some other autoimmune diseases, particularly Sjgren's syndrome (SjS; 36%) and systemic lupus erythematosus (SLE; 20%). Conclusions In summary, we found frequent anti-cN1A autoantibodies in sera from patients with IBM. Heterogeneity in reactivity with the three immunodominant epitopes indicates that serological assays should not be limited to a distinct epitope region. The similar reactivities observed for SjS and SLE demonstrate the need to further investigate whether distinct IBM-specific epitopes exist.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FE - Ostatní obory vnitřního lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Annals of the Rheumatic Diseases
ISSN
0003-4967
e-ISSN
—
Svazek periodika
75
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
6
Strana od-do
696-701
Kód UT WoS článku
000373403800021
EID výsledku v databázi Scopus
2-s2.0-84930014705